Kevin Harrington

Oct 9, 2024 | mdpi.com | Nikhil Patel |Pranav Patel |Ricky Bhogal |Kevin Harrington

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Aug 9, 2023 | oncologytube.com | Kevin Harrington

In the ever-evolving landscape of medical science, melanoma and Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) have remained two of the most formidable cancers to treat. Both of these cancers present unique challenges due to their aggressive nature and high recurrence rate. Yet, in the shadow of these challenges, targeted therapies have emerged as a beacon of hope. Targeted therapies are a relatively new addition to the oncological toolkit.